ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for PrEP Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-33Q18286
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Drugs for PrEP Market Research Report 2024
BUY CHAPTERS

Global Drugs for PrEP Market Research Report 2024

Code: QYRE-Auto-33Q18286
Report
October 2024
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
MSM
Gilead Sciences
ViiV Healthcare
TEVA
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan NV
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai-Tianqing Pharmaceutical

Drugs for PrEP Market

Drugs for Pre-Exposure Prophylaxis (PrEP) are antiretroviral medications used to prevent HIV infection in individuals at high risk of exposure. These drugs work by blocking the replication of HIV in the body if exposure occurs, significantly reducing the risk of infection. Taken daily, PrEP can lower HIV transmission risk by up to 99%. PrEP is recommended for individuals at high risk, such as men who have sex with men (MSM), people with HIV-positive partners, or those who engage in high-risk sexual activities or injectable drug use. In addition to oral medications, long-acting injectable forms like cabotegravir are being developed and used to enhance adherence and accessibility.
The global Drugs for PrEP market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Drugs for PrEP is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Drugs for PrEP is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Drugs for PrEP include Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for PrEP, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for PrEP.
The Drugs for PrEP market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Drugs for PrEP market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for PrEP manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Drugs for PrEP Market Report

Report Metric Details
Report Name Drugs for PrEP Market
Segment by Type
  • Oral Drugs
  • Injections
Segment by Application
  • Hospital and Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, North China Pharmaceutical, Chia Tai Tianqing Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Drugs for PrEP manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Drugs for PrEP in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Drugs for PrEP Market report?

Ans: The main players in the Drugs for PrEP Market are Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, North China Pharmaceutical, Chia Tai Tianqing Pharmaceutical

What are the Application segmentation covered in the Drugs for PrEP Market report?

Ans: The Applications covered in the Drugs for PrEP Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the Drugs for PrEP Market report?

Ans: The Types covered in the Drugs for PrEP Market report are Oral Drugs, Injections

Recommended Reports

HIV/AIDS Therapeutics

Drug Testing Markets

Prophylaxis & Prevention

1 Drugs for PrEP Market Overview
1.1 Product Definition
1.2 Drugs for PrEP by Type
1.2.1 Global Drugs for PrEP Market Value Comparison by Type (2024-2030)
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for PrEP by Application
1.3.1 Global Drugs for PrEP Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Drugs for PrEP Market Size Estimates and Forecasts
1.4.1 Global Drugs for PrEP Revenue 2019-2030
1.4.2 Global Drugs for PrEP Sales 2019-2030
1.4.3 Global Drugs for PrEP Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for PrEP Market Competition by Manufacturers
2.1 Global Drugs for PrEP Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for PrEP Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for PrEP Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Drugs for PrEP, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for PrEP, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for PrEP, Product Type & Application
2.7 Global Key Manufacturers of Drugs for PrEP, Date of Enter into This Industry
2.8 Global Drugs for PrEP Market Competitive Situation and Trends
2.8.1 Global Drugs for PrEP Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for PrEP Players Market Share by Revenue
2.8.3 Global Drugs for PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for PrEP Market Scenario by Region
3.1 Global Drugs for PrEP Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for PrEP Sales by Region: 2019-2030
3.2.1 Global Drugs for PrEP Sales by Region: 2019-2024
3.2.2 Global Drugs for PrEP Sales by Region: 2025-2030
3.3 Global Drugs for PrEP Revenue by Region: 2019-2030
3.3.1 Global Drugs for PrEP Revenue by Region: 2019-2024
3.3.2 Global Drugs for PrEP Revenue by Region: 2025-2030
3.4 North America Drugs for PrEP Market Facts & Figures by Country
3.4.1 North America Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for PrEP Sales by Country (2019-2030)
3.4.3 North America Drugs for PrEP Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for PrEP Market Facts & Figures by Country
3.5.1 Europe Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for PrEP Sales by Country (2019-2030)
3.5.3 Europe Drugs for PrEP Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for PrEP Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for PrEP Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for PrEP Sales by Region (2019-2030)
3.6.3 Asia Pacific Drugs for PrEP Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for PrEP Market Facts & Figures by Country
3.7.1 Latin America Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for PrEP Sales by Country (2019-2030)
3.7.3 Latin America Drugs for PrEP Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for PrEP Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for PrEP Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for PrEP Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for PrEP Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for PrEP Sales by Type (2019-2030)
4.1.1 Global Drugs for PrEP Sales by Type (2019-2024)
4.1.2 Global Drugs for PrEP Sales by Type (2025-2030)
4.1.3 Global Drugs for PrEP Sales Market Share by Type (2019-2030)
4.2 Global Drugs for PrEP Revenue by Type (2019-2030)
4.2.1 Global Drugs for PrEP Revenue by Type (2019-2024)
4.2.2 Global Drugs for PrEP Revenue by Type (2025-2030)
4.2.3 Global Drugs for PrEP Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for PrEP Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for PrEP Sales by Application (2019-2030)
5.1.1 Global Drugs for PrEP Sales by Application (2019-2024)
5.1.2 Global Drugs for PrEP Sales by Application (2025-2030)
5.1.3 Global Drugs for PrEP Sales Market Share by Application (2019-2030)
5.2 Global Drugs for PrEP Revenue by Application (2019-2030)
5.2.1 Global Drugs for PrEP Revenue by Application (2019-2024)
5.2.2 Global Drugs for PrEP Revenue by Application (2025-2030)
5.2.3 Global Drugs for PrEP Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for PrEP Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Sciences Drugs for PrEP Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.2.4 ViiV Healthcare Drugs for PrEP Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Teva
6.3.1 Teva Company Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Drugs for PrEP Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Amneal Pharmaceuticals
6.4.1 Amneal Pharmaceuticals Company Information
6.4.2 Amneal Pharmaceuticals Description and Business Overview
6.4.3 Amneal Pharmaceuticals Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amneal Pharmaceuticals Drugs for PrEP Product Portfolio
6.4.5 Amneal Pharmaceuticals Recent Developments/Updates
6.5 Aurobindo Pharma
6.5.1 Aurobindo Pharma Company Information
6.5.2 Aurobindo Pharma Description and Business Overview
6.5.3 Aurobindo Pharma Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Aurobindo Pharma Drugs for PrEP Product Portfolio
6.5.5 Aurobindo Pharma Recent Developments/Updates
6.6 Mylan
6.6.1 Mylan Company Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan Drugs for PrEP Product Portfolio
6.6.5 Mylan Recent Developments/Updates
6.7 Zydus
6.7.1 Zydus Company Information
6.7.2 Zydus Description and Business Overview
6.7.3 Zydus Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Zydus Drugs for PrEP Product Portfolio
6.7.5 Zydus Recent Developments/Updates
6.8 Qilu Pharmaceutical
6.8.1 Qilu Pharmaceutical Company Information
6.8.2 Qilu Pharmaceutical Description and Business Overview
6.8.3 Qilu Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharmaceutical Drugs for PrEP Product Portfolio
6.8.5 Qilu Pharmaceutical Recent Developments/Updates
6.9 Anhui Baker Biopharmaceutical
6.9.1 Anhui Baker Biopharmaceutical Company Information
6.9.2 Anhui Baker Biopharmaceutical Description and Business Overview
6.9.3 Anhui Baker Biopharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anhui Baker Biopharmaceutical Drugs for PrEP Product Portfolio
6.9.5 Anhui Baker Biopharmaceutical Recent Developments/Updates
6.10 Chengdu Brilliant Pharmaceutical
6.10.1 Chengdu Brilliant Pharmaceutical Company Information
6.10.2 Chengdu Brilliant Pharmaceutical Description and Business Overview
6.10.3 Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chengdu Brilliant Pharmaceutical Drugs for PrEP Product Portfolio
6.10.5 Chengdu Brilliant Pharmaceutical Recent Developments/Updates
6.11 North China Pharmaceutical
6.11.1 North China Pharmaceutical Company Information
6.11.2 North China Pharmaceutical Description and Business Overview
6.11.3 North China Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.11.4 North China Pharmaceutical Drugs for PrEP Product Portfolio
6.11.5 North China Pharmaceutical Recent Developments/Updates
6.12 Chia Tai Tianqing Pharmaceutical
6.12.1 Chia Tai Tianqing Pharmaceutical Company Information
6.12.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.12.3 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product Portfolio
6.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for PrEP Industry Chain Analysis
7.2 Drugs for PrEP Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for PrEP Production Mode & Process
7.4 Drugs for PrEP Sales and Marketing
7.4.1 Drugs for PrEP Sales Channels
7.4.2 Drugs for PrEP Distributors
7.5 Drugs for PrEP Customers
8 Drugs for PrEP Market Dynamics
8.1 Drugs for PrEP Industry Trends
8.2 Drugs for PrEP Market Drivers
8.3 Drugs for PrEP Market Challenges
8.4 Drugs for PrEP Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
MSM
Gilead Sciences
ViiV Healthcare
TEVA
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan NV
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
List of Tables
 Table 1. Global Drugs for PrEP Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Drugs for PrEP Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Drugs for PrEP Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Drugs for PrEP Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Drugs for PrEP Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Drugs for PrEP Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Drugs for PrEP Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Drugs for PrEP Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Drugs for PrEP, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Drugs for PrEP, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Drugs for PrEP, Product Type & Application
 Table 12. Global Key Manufacturers of Drugs for PrEP, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for PrEP by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for PrEP as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for PrEP Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Drugs for PrEP Sales by Region (2019-2024) & (K Units)
 Table 18. Global Drugs for PrEP Sales Market Share by Region (2019-2024)
 Table 19. Global Drugs for PrEP Sales by Region (2025-2030) & (K Units)
 Table 20. Global Drugs for PrEP Sales Market Share by Region (2025-2030)
 Table 21. Global Drugs for PrEP Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Drugs for PrEP Revenue Market Share by Region (2019-2024)
 Table 23. Global Drugs for PrEP Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Drugs for PrEP Revenue Market Share by Region (2025-2030)
 Table 25. North America Drugs for PrEP Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Drugs for PrEP Sales by Country (2019-2024) & (K Units)
 Table 27. North America Drugs for PrEP Sales by Country (2025-2030) & (K Units)
 Table 28. North America Drugs for PrEP Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Drugs for PrEP Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Drugs for PrEP Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Drugs for PrEP Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Drugs for PrEP Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Drugs for PrEP Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Drugs for PrEP Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Drugs for PrEP Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Drugs for PrEP Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Drugs for PrEP Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Drugs for PrEP Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Drugs for PrEP Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Drugs for PrEP Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Drugs for PrEP Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Drugs for PrEP Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Drugs for PrEP Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Drugs for PrEP Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Drugs for PrEP Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Drugs for PrEP Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Drugs for PrEP Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Drugs for PrEP Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Drugs for PrEP Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Drugs for PrEP Sales (K Units) by Type (2019-2024)
 Table 51. Global Drugs for PrEP Sales (K Units) by Type (2025-2030)
 Table 52. Global Drugs for PrEP Sales Market Share by Type (2019-2024)
 Table 53. Global Drugs for PrEP Sales Market Share by Type (2025-2030)
 Table 54. Global Drugs for PrEP Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Drugs for PrEP Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Drugs for PrEP Revenue Market Share by Type (2019-2024)
 Table 57. Global Drugs for PrEP Revenue Market Share by Type (2025-2030)
 Table 58. Global Drugs for PrEP Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Drugs for PrEP Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Drugs for PrEP Sales (K Units) by Application (2019-2024)
 Table 61. Global Drugs for PrEP Sales (K Units) by Application (2025-2030)
 Table 62. Global Drugs for PrEP Sales Market Share by Application (2019-2024)
 Table 63. Global Drugs for PrEP Sales Market Share by Application (2025-2030)
 Table 64. Global Drugs for PrEP Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Drugs for PrEP Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Drugs for PrEP Revenue Market Share by Application (2019-2024)
 Table 67. Global Drugs for PrEP Revenue Market Share by Application (2025-2030)
 Table 68. Global Drugs for PrEP Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Drugs for PrEP Price (US$/Unit) by Application (2025-2030)
 Table 70. Gilead Sciences Company Information
 Table 71. Gilead Sciences Description and Business Overview
 Table 72. Gilead Sciences Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Gilead Sciences Drugs for PrEP Product
 Table 74. Gilead Sciences Recent Developments/Updates
 Table 75. ViiV Healthcare Company Information
 Table 76. ViiV Healthcare Description and Business Overview
 Table 77. ViiV Healthcare Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. ViiV Healthcare Drugs for PrEP Product
 Table 79. ViiV Healthcare Recent Developments/Updates
 Table 80. Teva Company Information
 Table 81. Teva Description and Business Overview
 Table 82. Teva Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Teva Drugs for PrEP Product
 Table 84. Teva Recent Developments/Updates
 Table 85. Amneal Pharmaceuticals Company Information
 Table 86. Amneal Pharmaceuticals Description and Business Overview
 Table 87. Amneal Pharmaceuticals Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Amneal Pharmaceuticals Drugs for PrEP Product
 Table 89. Amneal Pharmaceuticals Recent Developments/Updates
 Table 90. Aurobindo Pharma Company Information
 Table 91. Aurobindo Pharma Description and Business Overview
 Table 92. Aurobindo Pharma Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Aurobindo Pharma Drugs for PrEP Product
 Table 94. Aurobindo Pharma Recent Developments/Updates
 Table 95. Mylan Company Information
 Table 96. Mylan Description and Business Overview
 Table 97. Mylan Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Mylan Drugs for PrEP Product
 Table 99. Mylan Recent Developments/Updates
 Table 100. Zydus Company Information
 Table 101. Zydus Description and Business Overview
 Table 102. Zydus Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Zydus Drugs for PrEP Product
 Table 104. Zydus Recent Developments/Updates
 Table 105. Qilu Pharmaceutical Company Information
 Table 106. Qilu Pharmaceutical Description and Business Overview
 Table 107. Qilu Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Qilu Pharmaceutical Drugs for PrEP Product
 Table 109. Qilu Pharmaceutical Recent Developments/Updates
 Table 110. Anhui Baker Biopharmaceutical Company Information
 Table 111. Anhui Baker Biopharmaceutical Description and Business Overview
 Table 112. Anhui Baker Biopharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Anhui Baker Biopharmaceutical Drugs for PrEP Product
 Table 114. Anhui Baker Biopharmaceutical Recent Developments/Updates
 Table 115. Chengdu Brilliant Pharmaceutical Company Information
 Table 116. Chengdu Brilliant Pharmaceutical Description and Business Overview
 Table 117. Chengdu Brilliant Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Chengdu Brilliant Pharmaceutical Drugs for PrEP Product
 Table 119. Chengdu Brilliant Pharmaceutical Recent Developments/Updates
 Table 120. North China Pharmaceutical Company Information
 Table 121. North China Pharmaceutical Description and Business Overview
 Table 122. North China Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. North China Pharmaceutical Drugs for PrEP Product
 Table 124. North China Pharmaceutical Recent Developments/Updates
 Table 125. Chia Tai Tianqing Pharmaceutical Company Information
 Table 126. Chia Tai Tianqing Pharmaceutical Description and Business Overview
 Table 127. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Chia Tai Tianqing Pharmaceutical Drugs for PrEP Product
 Table 129. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Drugs for PrEP Distributors List
 Table 133. Drugs for PrEP Customers List
 Table 134. Drugs for PrEP Market Trends
 Table 135. Drugs for PrEP Market Drivers
 Table 136. Drugs for PrEP Market Challenges
 Table 137. Drugs for PrEP Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for PrEP
 Figure 2. Global Drugs for PrEP Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Drugs for PrEP Market Share by Type: 2023 & 2030
 Figure 4. Oral Drugs Product Picture
 Figure 5. Injections Product Picture
 Figure 6. Global Drugs for PrEP Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Drugs for PrEP Market Share by Application: 2023 & 2030
 Figure 8. Hospital and Clinic
 Figure 9. Pharmacy
 Figure 10. Other
 Figure 11. Global Drugs for PrEP Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Drugs for PrEP Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Drugs for PrEP Sales (2019-2030) & (K Units)
 Figure 14. Global Drugs for PrEP Average Price (US$/Unit) & (2019-2030)
 Figure 15. Drugs for PrEP Report Years Considered
 Figure 16. Drugs for PrEP Sales Share by Manufacturers in 2023
 Figure 17. Global Drugs for PrEP Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Drugs for PrEP Players: Market Share by Revenue in Drugs for PrEP in 2023
 Figure 19. Drugs for PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Drugs for PrEP Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Drugs for PrEP Sales Market Share by Country (2019-2030)
 Figure 22. North America Drugs for PrEP Revenue Market Share by Country (2019-2030)
 Figure 23. United States Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Drugs for PrEP Sales Market Share by Country (2019-2030)
 Figure 26. Europe Drugs for PrEP Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Drugs for PrEP Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Drugs for PrEP Revenue Market Share by Region (2019-2030)
 Figure 34. China Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Drugs for PrEP Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Drugs for PrEP Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Drugs for PrEP Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Drugs for PrEP Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Drugs for PrEP by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Drugs for PrEP by Type (2019-2030)
 Figure 53. Global Drugs for PrEP Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Drugs for PrEP by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Drugs for PrEP by Application (2019-2030)
 Figure 56. Global Drugs for PrEP Price (US$/Unit) by Application (2019-2030)
 Figure 57. Drugs for PrEP Value Chain
 Figure 58. Drugs for PrEP Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Pre Exposure Prophylaxis PrEP Market Research Report 2024
Pre Exposure Prophylaxis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Parenteral PrEP Market Research Report 2024
Global Long acting PrEP Market Research Report 2024
Global Injectable HIV Medication Market Research Report 2024
Global Injectable HIV Treatment Market Research Report 2024
Global Long acting Anti HIV Drugs Market Research Report 2024
Prophylactic HIV Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global HIV Prevention Drug Market Research Report 2024
Global Tenofovir Fumarate Market Research Report 2024
Global HIV Therapy Market Research Report 2025
Stavudine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
HIV Antiretroviral Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Letermovir API Market Research Report 2024
Protease Inhibitors Market
Global Enfuvirtide for Injection Market Research Report 2024
Global HIV 1 RT Inhibitors Market Research Report 2024
Global Drug for Organ Rejection Prophylaxis Market Research Report 2025
Global Premade Lentivirus and Custom Lentivirus Production Services Market Research Report 2024
Antiretroviral Protease Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19B19893
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30B3636
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3H1702
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13C3384
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions